Latest Period
Q4 2025
Security Snapshot
Prime Medicine, Inc. - COMMON STOCK (PRME) Institutional Ownership
CUSIP: 74168J101
13F Institutional Holders and Ownership History from Q4 2022 to Q1 2026
Institutions Reporting
181
Shares (Excl. Options)
97,023,450
Price
$3.47
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- PRME on Nasdaq
- Shares outstanding
- 181,672,212
- Price per share
- $3.43
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 97,023,450
- Total reported value
- $336,613,421
- % of total 13F portfolios
- 0%
- Share change
- +4,676,215
- Value change
- +$756,588
- Number of holders
- 181
- Price from insider filings
- $3.43
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PRME - Prime Medicine, Inc. - COMMON STOCK is tracked under CUSIP 74168J101.
- 181 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 181 to 111 between Q4 2025 and Q1 2026.
- Reported value moved from $336,613,421 to $185,221,129.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 181 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 74168J101?
CUSIP 74168J101 identifies PRME - Prime Medicine, Inc. - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74168J101:
Significant Owners of Prime Medicine, Inc. - COMMON STOCK (PRME) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 10% | $80,853,607 | 18,587,036 | Robert Nelsen | 07 Aug 2025 | |||
| GV 2019, L.P. | 12% | $91,756,239 | 16,562,498 | Alphabet Holdings LLC | 30 Sep 2025 | |||
| FMR LLC | 3.8% | $37,294,150 | 6,731,796 | FMR LLC | 30 Sep 2025 | |||
| Newpath Partners, L.P. | 4.7% | $9,769,086 | 6,105,679 | Newpath Partners, L.P. | 31 Dec 2024 | |||
| T. Rowe Price Investment Management, Inc. | 3.3% | -40% | $25,659,383 | -$13,874,784 | 5,995,183 | -35% | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 |
As of 31 Dec 2025, 181 institutional investors reported holding 97,023,450 shares of Prime Medicine, Inc. - COMMON STOCK (PRME). This represents 53% of the company’s total 181,672,212 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Prime Medicine, Inc. - COMMON STOCK (PRME) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Alphabet Inc. | 9.1% | 16,562,498 | 0% | 2.2% | $57,471,868 |
| BlackRock, Inc. | 4.6% | 8,268,843 | +46% | 0% | $28,692,886 |
| VANGUARD GROUP INC | 3.6% | 6,467,872 | +31% | 0% | $22,443,516 |
| T. Rowe Price Investment Management, Inc. | 3.3% | 5,995,183 | -35% | 0.01% | $20,804,000 |
| ARK Investment Management LLC | 3% | 5,368,526 | -2% | 0.12% | $18,628,784 |
| STATE STREET CORP | 2.8% | 5,095,510 | +293% | 0% | $17,681,420 |
| Sumitomo Mitsui Trust Group, Inc. | 1.8% | 3,245,506 | -11% | 0.01% | $11,261,906 |
| Amova Asset Management Americas, Inc. | 1.8% | 3,245,506 | -11% | 0.13% | $11,196,996 |
| Casdin Capital, LLC | 1.7% | 3,167,175 | 0% | 0.68% | $10,990,097 |
| Balyasny Asset Management L.P. | 1.7% | 3,124,362 | +6426% | 0.02% | $10,841,536 |
| Woodline Partners LP | 1.7% | 3,002,844 | +0.01% | 0.04% | $10,419,869 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 2,628,429 | +49% | 0% | $9,123,032 |
| UBS Group AG | 1.3% | 2,440,583 | +701% | 0% | $8,468,823 |
| FMR LLC | 1.2% | 2,176,646 | -23% | 0% | $7,552,961 |
| MWG Caph Ltd | 0.99% | 1,792,210 | 0% | 8.6% | $6,218,969 |
| GOLDMAN SACHS GROUP INC | 0.97% | 1,755,768 | +327% | 0% | $6,092,515 |
| TWO SIGMA INVESTMENTS, LP | 0.9% | 1,629,324 | +264% | 0.01% | $5,653,754 |
| D. E. Shaw & Co., Inc. | 0.85% | 1,551,369 | -30% | 0% | $5,383,250 |
| FARALLON CAPITAL MANAGEMENT LLC | 0.68% | 1,240,843 | -74% | 0.02% | $4,305,725 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.65% | 1,176,727 | +101% | 0.01% | $4,083,243 |
| MORGAN STANLEY | 0.64% | 1,169,898 | +60% | 0% | $4,059,547 |
| RENAISSANCE TECHNOLOGIES LLC | 0.63% | 1,149,159 | +1.3% | 0.01% | $3,987,582 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.52% | 936,815 | +63% | 0% | $3,250,748 |
| NORTHERN TRUST CORP | 0.46% | 842,153 | +39% | 0% | $2,922,271 |
| Greenwich Wealth Management LLC | 0.41% | 740,001 | +2.8% | 0.11% | $2,568,000 |
Institutional Holders of Prime Medicine, Inc. - COMMON STOCK (PRME) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 53,315,719 | $185,221,129 | +$8,674,733 | $3.48 | 111 |
| 2025 Q4 | 97,023,450 | $336,613,421 | +$756,588 | $3.47 | 181 |
| 2025 Q3 | 92,347,818 | $511,536,971 | +$186,859,809 | $5.54 | 165 |
| 2025 Q2 | 58,654,950 | $144,864,309 | -$2,708,584 | $2.47 | 118 |
| 2025 Q1 | 60,327,480 | $120,048,763 | -$9,144,075 | $1.99 | 121 |
| 2024 Q4 | 64,302,617 | $187,767,212 | -$16,411,951 | $2.92 | 128 |
| 2024 Q3 | 68,711,037 | $265,862,243 | -$1,687,770 | $3.87 | 113 |
| 2024 Q2 | 68,888,470 | $353,995,003 | +$8,574,594 | $5.14 | 119 |
| 2024 Q1 | 66,659,039 | $466,578,147 | +$125,445,462 | $7.00 | 112 |
| 2023 Q4 | 48,691,116 | $431,437,073 | -$10,408,984 | $8.86 | 102 |
| 2023 Q3 | 49,517,421 | $472,282,828 | +$28,502,950 | $9.54 | 82 |
| 2023 Q2 | 46,131,758 | $675,732,293 | +$67,078,075 | $14.65 | 77 |
| 2023 Q1 | 41,738,575 | $512,085,492 | +$2,897,210 | $12.30 | 73 |
| 2022 Q4 | 41,322,385 | $767,784,036 | +$767,085,261 | $18.58 | 65 |